The BCR-ABL hybrid gene, the molecular hallmark of CML [3] encodes an oncogenic fusion protein harboring a deregulated tyrosine kinase activity that is responsible for leukemogenesis in vitro and in vivo [4, 5]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.